The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Primary biliary cirrhosis
Open accessAbstract
Primary biliary cirrhosis (PBC) is an immune-mediated chronic cholestatic liver disease with a slowly progressive course. Without treatment, most patients eventually develop fibrosis and cirrhosis of the liver and may need liver transplantation in the late stage of disease. PBC primarily affects women (female preponderance 9-10:1) with a prevalence of up to 1 in 1,000 women over 40 years of age. Common symptoms of the disease are fatigue and pruritus, but most patients are asymptomatic at first presentation. The diagnosis is based on sustained elevation of serum markers of cholestasis, i.e., alkaline phosphatase and gamma-glutamyl transferase, and the presence of serum antimitochondrial antibodies directed against the E2 subunit of the pyruvate dehydrogenase complex. Histologically, PBC is characterized by florid bile duct lesions with damage to biliary epithelial cells, an often dense portal inflammatory infiltrate and progressive loss of small intrahepatic bile ducts. Although the insight into pathogenetic aspects of PBC has grown enormously during the recent decade and numerous genetic, environmental, and infectious factors have been disclosed which may contribute to the development of PBC, the precise pathogenesis remains enigmatic. Ursodeoxycholic acid (UDCA) is currently the only FDA-approved medical treatment for PBC. When administered at adequate doses of 13-15 mg/kg/day, up to two out of three patients with PBC may have a normal life expectancy without additional therapeutic measures. The mode of action of UDCA is still under discussion, but stimulation of impaired hepatocellular and cholangiocellular secretion, detoxification of bile, and antiapoptotic effects may represent key mechanisms. One out of three patients does not adequately respond to UDCA therapy and may need additional medical therapy and/or liver transplantation. This review summarizes current knowledge on the clinical, diagnostic, pathogenetic, and therapeutic aspects of PBC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Hulley, S. (1998) · JAMA · doi:10.1001/jama.280.7.605 · Cited by 6,216
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease
Ueda, H., Howson, J. M. M., Esposito, L., Heward, J., Snook, Chamberlain, G., Rainbow, D. B., Hunter, K. M. D., Smith, A. N., Di Genova, G., et al. (2003) · Nature · doi:10.1038/nature01621 · Cited by 2,175 · cited 1×
“Allelic variations of tumor necrosis factor α (TNFα) and of cytotoxic T lymphocyte antigen 4 (CTLA-4), a key regulator of the adaptive immune system, have been repeatedly associated with susceptibility to different autoimmune diseases (such as type I diabetes mellitus and systemic lupus erythematosus) and were also as…”
BackgroundEASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
Kaplan, M. M., & Gershwin, M. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043898 · Cited by 1,144
Prognosis in primary biliary cirrhosis: Model for decision making
Dickson, R. E., Grambsch, P. M., Fleming, T. R., Fisher, L. D., & Langworthy, A. (1989) · Hepatology · doi:10.1002/hep.1840100102 · Cited by 816 · cited 2×
“The vaccine contained Lactobacillus salivarius, which exerts a high homology to the beta-galactosidase of Lactobacillus delbrueckii (LACDE BGAL [266] [267] [268] [269] [270] [271] [272] [273] [274] [275] [276] [277] [278] [279] [280] , and cross-reactivity of patients' autoantibodies against the human PDC-E2 212-226 e…”
BackgroundParés, A., Caballería, L., & Rodés, J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.12.029 · Cited by 756 · cited 2×
““Response” here is defined as a decrease in AP to <40% of pretreatment levels or normalization at 1 year (Barcelona criteria) [12] or serum bilirubin <1 mg/dl, AP≤3 × N and AST≤2 × N after 1 year of UDCA treatment (Paris criteria) [13, 14].”
BackgroundA Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Balkau, B., Eschwège, E., Poupon, R., & the UDCA–PBC Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199105303242204 · Cited by 755
Paumgartner, G., & Beuers, U. (2002) · Hepatology · doi:10.1053/jhep.2002.36088 · Cited by 748
Self-citationCarey, E. J., Ali, A. H., & Lindor, K. D. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00154-3 · Cited by 735
Poupon, R., Lindor, K., Cauch-Dudek, K., Dickson, E., Poupon, R., & Heathcote, E. (1997) · Gastroenterology · doi:10.1016/s0016-5085(97)70183-5 · Cited by 648
Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis
Corpechot, C., Abenavoli, L., Rabahi, N., Chrétien, Y., Andréani, T., Johanet, C., Chazouillères, O., & Poupon, R. (2008) · Hepatology · doi:10.1002/hep.22428 · Cited by 646 · cited 2×
““Response” here is defined as a decrease in AP to <40% of pretreatment levels or normalization at 1 year (Barcelona criteria) [12] or serum bilirubin <1 mg/dl, AP≤3 × N and AST≤2 × N after 1 year of UDCA treatment (Paris criteria) [13, 14].”
BackgroundGershwin, E. M., Selmi, C., Worman, H. J., Gold, E. B., Watnik, M., Utts, J., Lindor, K. D., Kaplan, M. M., & Vierling, J. M. (2005) · Hepatology · doi:10.1002/hep.20907 · Cited by 621
Primary Biliary Cirrhosis Associated with HLA, IL12A, and IL12RB2 Variants
Hirschfield, G. M., Liu, X., Xu, C., Lu, Y., Xie, G., Lu, Y., Gu, X., Walker, E. J., Jing, K., Juran, B. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810440 · Cited by 594
The presentation and diagnosis of 100 patients with primary biliary cirrhosis
Sherlock, S., & Scheuer, P. J. (1973) · New England Journal of Medicine · doi:10.1056/nejm197309272891306 · Cited by 504 · cited 3×
“In the Western literature, the beneficial effects of UDCA on serum liver tests for patients with hepatic disorders were first reported in the 1980s [213, 214], and UDCA has since been established for the treatment of PBC. Today, it is the only FDA-approved drug and standard therapy for PBC. UDCA was shown to improve s…”
BackgroundUrsodeoxycholic acid in the treatment of primary biliary cirrhosis
Lindor, K. D., Dickson, E. R., Baldus, W. P., Jorgensen, R. A., Ludwig, J., Murtaugh, P. A., Harrison, J. M., Wiesner, R. H., Anderson, M. L., Lange, S. M., et al. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90021-3 · Cited by 487 · cited 2×
“UDCA was shown to improve serum biochemical markers such as bilirubin, AP, γGT, cholesterol, and IgM levels [215] [216] [217] [218] [219] [220] .”
BackgroundPrimary biliary cirrhosis in monozygotic and dizygotic twins: Genetics, epigenetics, and environment
Selmi, C., Mayo, M. J., Bach, N., Ishibashi, H., Invernizzi, P., Gish, R. G., Gordon, S. C., Wright, H. I., Zweiban, B., Podda, M., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.05.005 · Cited by 480
Natural history of early primary biliary cirrhosis
Metcalf, J. V., Mitchison, H. C., Palmer, J. M., Jones, D. E., Bassendine, M. F., & James, O. F. (1996) · The Lancet · doi:10.1016/s0140-6736(96)04410-8 · Cited by 421 · cited 1×
“cholestasis and 22 became symptomatic [37], confirming a high positive predictive value of positive AMA testing for the development of PBC.”
BackgroundRoll, J., Boyer, J. L., Barry, D., & Klatskin, G. (1983) · New England Journal of Medicine · doi:10.1056/nejm198301063080101 · Cited by 417 · cited 1×
“Findings of fibrotic or cirrhotic changes (stage 3 or 4) are accompanied by a worse prognosis [54].”
BackgroundDrug Insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis
Beuers, U. (2006) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0521 · Cited by 417
Self-citationEpidemiology and natural history of primary biliary cirrhosis in a U.S. community
Kim, W. R., Lindor, K. D., Locke, G. R., Therneau, T. M., Homburger, H. A., Batts, K. P., Yawn, B. P., Petz, J. L., Melton, L. J., & Dickson, E. R. (2000) · Gastroenterology · doi:10.1053/gast.2000.20197 · Cited by 349
Corpechot, C., Carrat, F., Bonnand, A.-M., Poupon, R. E., & Poupon, R. (2000) · Hepatology · doi:10.1053/jhep.2000.20240 · Cited by 316
Goulis, J., Leandro, G., & Burroughs, A. K. (1999) · The Lancet · doi:10.1016/s0140-6736(98)11293-x · Cited by 315 · cited 1×
“Also, a meta-analysis of 11 randomized trials could not confirm a significant effect of UDCA on survival and incidence of liver transplantation [275].”
BackgroundPatients With Primary Biliary Cirrhosis React Against A Ubiquitous Xenobiotic–Metabolizing Bacterium
Selmi, C., Balkwill, D. L., Invernizzi, P., Ansari, A. A., Coppel, R. L., Podda, M., Leung, P. S., Kenny, T. P., Van De Water, J., Nantz, M. H., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50446 · Cited by 312
A controlled trial of naloxone infusions for the pruritus of chronic cholestasis
Bergasa, N. V., Talbot, T. L., Alling, D. W., Schmitt, J. M., Walker, E. C., Baker, B. L., Korenman, J. C., Park, Y., Hoofnagle, J. H., & Jones, E. A. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)90102-5 · Cited by 287 · cited 1×
“As a thirdline option, (3) opioid antagonists (naloxone, nalmefene, naltrexone) have been found to reduce itch severity in patients with PBC [298, [302] [303] [304] .”
Treatment of pruritus of primary biliary cirrhosis with rifampin
Podesta, A., Lopez, P., Terg, R., Villamil, F., Flores, D., Mastai, R., Udaondo, C. B., & Companc, J. P. (1991) · Digestive Diseases and Sciences · doi:10.1007/bf01300759 · Cited by 267
Impact of fatigue on the quality of life of patients with primary biliary cirrhosis
Huet, P.-M., Deslauriers, J., Tran, A., Faucher, C., & Charbonneau, J. (2000) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.01857.x · Cited by 262
Prince, M. I., Chetwynd, A., Craig, W. L., Metcalf, J. V., & James, O. F. W. (2004) · Gut · doi:10.1136/gut.2003.023937 · Cited by 261 · cited 2×
“In the majority of asymptomatic and untreated patients, overt symptoms develop within 2 to 4 years, although one third may remain symptom-free for many years [27, 56].”
BackgroundTreatment of pruritus in primary biliary cirrhosis with rifampin
Ghent, C. N., & Carruthers, S. G. (1988) · Gastroenterology · doi:10.1016/0016-5085(88)90442-8 · Cited by 257
Leuschner, M., Maier, K., Schlichting, J., Strahl, S., Herrmann, G., Dahm, H. H., Ackermann, H., Happ, J., & Leuschner, U. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70351-3 · Cited by 247
Guidelines on the management of osteoporosis associated with chronic liver disease
Collier, J. D., Ninkovic, M., & Compston, J. E. (2002) · Gut · doi:10.1136/gut.50.suppl_1.i1 · Cited by 241 · cited 1×
“Calcium and vitamin D supplementation is usually recommended in osteoporosis, although their role in preventing osteoporosis and fracture in chronic liver disease is unclear [319, 320].”
BackgroundFatigue in primary biliary cirrhosis
Cauch-Dudek, K., Abbey, S., Stewart, D. E., & Heathcote, E. J. (1998) · Gut · doi:10.1136/gut.43.5.705 · Cited by 237
Michieletti, P., Wanless, I. R., Katz, A., Scheuer, P. J., Yeaman, S. J., Bassendine, M. F., Palmer, J. M., & Heathcote, E. J. (1994) · Gut · doi:10.1136/gut.35.2.260 · Cited by 236
Effects of long-term rifampicin administration in primary biliary cirrhosis
Bachs, L., Parés, A., Elena, M., Piera, C., & Rodés, J. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)90335-v · Cited by 235
IL-2 receptor α−/− mice and the development of primary biliary cirrhosis
Wakabayashi, K., Lian, Z.-X., Moritoki, Y., Lan, R. Y., Tsuneyama, K., Chuang, Y.-H., Yang, G.-X., Ridgway, W., Ueno, Y., Ansari, A. A., et al. (2006) · Hepatology · doi:10.1002/hep.21385 · Cited by 233
Mitchison, H. C., Bassendine, M. F., Hendrick, A., Bennett, M. K., Bird, G., Watson, A. J., & James, O. F. W. (1986) · Hepatology · doi:10.1002/hep.1840060609 · Cited by 230
Schoemaker, M. H., de la Rosa, L. C., Buist-Homan, M., Vrenken, T. E., Havinga, R., Poelstra, K., Haisma, H. J., Jansen, P. L. M., & Moshage, H. (2004) · Hepatology · doi:10.1002/hep.20246 · Cited by 229 · cited 2×
“Inhibition of apoptosis Hydrophobic bile salts induce hepatocellular apoptosis [247–249] by death receptordependent [250, 251] and -independent [252, 253] mechanisms, an effect that may become relevant when bile salts accumulate in the liver in cholestatic states.”
BackgroundKita, H., Matsumura, S., He, X.-S., Ansari, A. A., Lian, Z.-X., Van de Water, J., Coppel, R. L., Kaplan, M. M., & Gershwin, M. E. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0214698 · Cited by 222
Rautiainen, H., Kärkkäinen, P., Karvonen, A., Nurmi, H., Pikkarainen, P., Nuutinen, H., & Färkkilä, M. (2005) · Hepatology · doi:10.1002/hep.20646 · Cited by 222
Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites
Ala, A., Stanca, C. M., Bu-Ghanim, M., Ahmado, I., Branch, A. D., Schiano, T. D., Odin, J. A., & Bach, N. (2006) · Hepatology · doi:10.1002/hep.21076 · Cited by 222 · cited 1×
“Another recent study from New York examined the prevalence of PBC and PSC near superfund areas and reported significant clusters of PBC surrounding toxic sites [128] .”
BackgroundOdin, J. A., Huebert, R. C., Casciola-Rosen, L., LaRusso, N. F., & Rosen, A. (2001) · Journal of Clinical Investigation · doi:10.1172/jci200110716 · Cited by 220
Bacteriuria and primary biliary cirrhosis.
Burroughs, A. K., Rosenstein, I. J., Epstein, O., Hamilton-Miller, J. M., Brumfitt, W., & Sherlock, S. (1984) · Gut · doi:10.1136/gut.25.2.133 · Cited by 214 · cited 2×
“Though often asymptomatic, recurrent urinary tract infections have been reported in up to 19% of women with PBC [73], and a potential pathophysiologic relevance of Escherichia coli strains has been suggested.”
BackgroundPrimary biliary cirrhosis once rare, now common in the United Kingdom?
James, O. F., Bhopal, R., Howel, D., Gray, J., Burt, A. D., & Metcalf, J. V. (1999) · Hepatology · doi:10.1002/hep.510300213 · Cited by 213
Familial primary biliary cirrhosis reassessed: a geographically-based population study
Jones, D. E., Watt, F. E., Metcalf, J. V., Bassendine, M. F., & James, O. F. W. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80097-x · Cited by 213
Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis
Poupon, R. E., Bonnand, A.-M., Chrétien, Y., & Poupon, R. (1999) · Hepatology · doi:10.1002/hep.510290603 · Cited by 209
Jones, A. E., & Bergasa, N. V. (1999) · Hepatology · doi:10.1002/hep.510290450 · Cited by 202
Kaya, M., Angulo, P., & Lindor, K. D. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80004-5 · Cited by 193
Amano, K., Leung, P. S. C., Rieger, R., Quan, C., Wang, X., Marik, J., Suen, Y. F., Kurth, M. J., Nantz, M. H., Ansari, A. A., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.9.5874 · Cited by 187
Altered Monocyte Responses to Defined TLR Ligands in Patients With Primary Biliary Cirrhosis *
Mao, T. K., Lian, Z.-X., Selmi, C., Ichiki, Y., Ashwood, P., Ansari, A. A., Coppel, R. L., Shimoda, S., Ishibashi, H., & Gershwin, E. M. (2005) · Hepatology · doi:10.1002/hep.20859 · Cited by 185 · cited 1×
“In combination, presence of cross-reactive antigens in a proinflammatory environment would theoretically be able to break tolerance [133, 134].”
BackgroundOpen‐label trial of oral nalmefene therapy for the pruritus of cholestasis
Bergasa, N. V., Schmitt, J. M., Talbot, T. L., Alling, D. W., Swain, M. G., Turner, M. L., Jenkins, J. B., & Jones, A. E. (1998) · Hepatology · doi:10.1002/hep.510270307 · Cited by 182
Tandon, P., Rowe, B. H., Vandermeer, B., & Bain, V. G. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01200.x · Cited by 176 · cited 2×
“At present, no convincing data for an antipruritic effect of UDCA in PBC are available [298].”
BackgroundHepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes
Jones, D. E., Metcalf, J. V., Collier, J. D., Bassendine, M. F., & James, O. F. (1997) · Hepatology · doi:10.1002/hep.510260508 · Cited by 161
Randomized trial of chlorambucil for primary biliary cirrhosis
Hoofnagle, J. H., Davis, G. L., Schafer, D. F., Peters, M., Avigan, M. I., Pappas, S. C., Hanson, R. G., Minuk, G. Y., Dusheiko, G. M., Campbell, G., et al. (1986) · Gastroenterology · doi:10.1016/0016-5085(86)90183-6 · Cited by 157
Iwasaki, S., Ohira, H., Nishiguchi, S., Zeniya, M., Kaneko, S., Onji, M., Ishibashi, H., Sakaida, I., Kuriyama, S., Ichida, T., et al. (2008) · Hepatology Research · doi:10.1111/j.1872-034x.2007.00305.x · Cited by 145
Zein, C. O., Jorgensen, R. A., Clarke, B., Wenger, D. E., Keach, J. C., Angulo, P., & Lindor, K. D. (2005) · Hepatology · doi:10.1002/hep.20866 · Cited by 142
Natural history of pruritus in primary biliary cirrhosis
Talwalkar, J. A., Souto, E., Jorgensen, R. A., & Lindor, K. D. (2003) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(03)00134-4 · Cited by 141
Estrogen receptors in cholangiocytes and the progression of primary biliary cirrhosis
Alvaro, D., Invernizzi, P., Onori, P., Franchitto, A., De Santis, A., Crosignani, A., Sferra, R., Ginanni-Corradini, S., Grazia Mancino, M., Maggioni, M., et al. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.08.022 · Cited by 134 · cited 1×
“At the tissue level, cholangiocytes from PBC patients in the earliest disease stages (but not cholangiocytes from normal controls) express estrogen receptors [121].”
BackgroundMoteki, S., Leung, P. S., Dickson, E. R., Van Thiel, D. H., Galperin, C., Buch, T., Alarcon-Segovia, D., Kershenobich, D., Kawano, K., Coppel, R. L., et al. (1996) · Hepatology · doi:10.1002/hep.510230307 · Cited by 133 · cited 1×
“Previous studies have demonstrated that the dominant epitopes recognized by AMA are all located within these lipoyl domains of the target antigens [185] [186] [187] [188] .”
BackgroundGong, Y., Huang, Z., Christensen, E., & Gluud, C. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01235.x · Cited by 131 · cited 1×
“similar shortcomings [276, 277] and may therefore have missed a beneficial effect of UDCA.”
BackgroundLeuschner, M., Güldütuna, S., You, T., Hübner, K., Bhatti, S., & Leuschner, U. (1996) · Journal of Hepatology · doi:10.1016/s0168-8278(96)80327-8 · Cited by 119 · cited 1×
“Combination of UDCA and prednisolone in comparison to UDCA alone resulted in a significant improvement of histological features [282] .”
ResultGuañabens, N., Parés, A., Ros, I., Alvarez, L., Pons, F., Caballería, L., Monegal, A., de Osaba, J. M. M., Roca, M., Peris, P., et al. (2003) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07639.x · Cited by 119 · cited 1×
“In two controlled trials however, alendronate significantly improved spine and femoral bone mineral density compared with placebo and had greater antiresorptive activity than etidronate [329, 330] .”
BackgroundHepatocellular carcinoma and survival in patients with primary biliary cirrhosis
Shibuya, A., Tanaka, K., Miyakawa, H., Shibata, M., Takatori, M., Sekiyama, K., Hashimoto, N., Amaki, S., Komatsu, T., & Morizane, T. (2002) · Hepatology · doi:10.1053/jhep.2002.33157 · Cited by 116
JONES, D. E. J., & NEWTON, J. L. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03223.x · Cited by 114 · cited 1×
“In a series of 21 PBC patients with excessive daytime sleepiness [313], the centrally acting agent modafinil was investigated in an open-label study [314].”
BackgroundIncidence of cancer in primary biliary cirrhosis: the Mayo experience
Nijhawan, P. K., Therneau, T. M., Dickson, R. E., Boynton, J., & Lindor, K. D. (1999) · Hepatology · doi:10.1002/hep.510290511 · Cited by 99 · cited 1×
“Hepatocellular carcinoma in late-stage PBC has been reported to occur at rates similar to other kinds of cirrhosis [77] [78] [79] , but seems to be more frequent in men with PBC:”
BackgroundTaylor, S. L., Dean, P. J., & Riely, C. A. (1994) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199401000-00009 · Cited by 95
Natural history of primary biliary cirrhosis
Parés, A., & Rodés, J. (2003) · Clinics in Liver Disease · doi:10.1016/s1089-3261(03)00100-4 · Cited by 89
Huet, P., Vincent, C., Deslaurier, J., Coté, J., Matsutami, S., Boileau, R., & Huet–van Kerckvoorde, J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.07.019 · Cited by 84
Theal, J. J., Toosi, M. N., Girlan, L., Heslegrave, R. J., Huet, P., Burak, K. W., Swain, M., Tomlinson, G. A., & Heathcote, E. J. (2005) · Hepatology · doi:10.1002/hep.20698 · Cited by 73
Primary biliary cirrhosis, sicca complex, and dysphagia
Mang, F.-W., Michieletti, P., O'Rourke, K., Cauch-Dudek, K., Diamant, N., Bookman, A., & Heathcote, J. (1997) · Dysphagia · doi:10.1007/pl00009532 · Cited by 57
Talwalkar, J. A., Donlinger, J. J., Gossard, A. A., Keach, J. C., Jorgensen, R. A., Petz, J. C., & Lindor, K. D. (2006) · Digestive Diseases and Sciences · doi:10.1007/s10620-006-9397-5 · Cited by 54 · cited 1×
“The selective serotonin reuptake inhibitors fluvoxamine and fluoxetine also failed to exert beneficial effects on fatigue in this patient group [311, 312].”
BackgroundHypercholesterolemia in Primary Biliary Cirrhosis
Su, T.-C., Hwang, J.-J., & Kao, J.-H. (2007) · New England Journal of Medicine · doi:10.1056/nejmc071467 · Cited by 31 · cited 1×
“LpX is not taken up in atherosclerotic plaques and may reduce the atherogenicity of low-density lipoprotein (LDL) cholesterol by preventing LDL oxidation [34].”
Background
Cited by
Hohenester, S., de Buy Wenniger, L. M., Paulusma, C. C., van Vliet, S. J., Jefferson, D. M., Oude Elferink, R. P., & Beuers, U. (2012) · Hepatology · doi:10.1002/hep.24691 · Cited by 315
Self-citationFarnesoid X receptor targeting to treat nonalcoholic steatohepatitis
Adorini, L., Pruzanski, M., & Shapiro, D. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.05.012 · Cited by 259
Banales, J. M., Sáez, E., Úriz, M., Sarvide, S., Urribarri, A. D., Splinter, P., Tietz Bogert, P. S., Bujanda, L., Prieto, J., Medina, J. F., et al. (2012) · Hepatology · doi:10.1002/hep.25691 · Cited by 250
UDCA exerts beneficial effect on mitochondrial dysfunction in LRRK2 G2019S carriers and in vivo
Mortiboys, H., Furmston, R., Bronstad, G., Aasly, J., Elliott, C., & Bandmann, O. (2015) · Neurology · doi:10.1212/wnl.0000000000001905 · Cited by 131
He, H., Mennone, A., Boyer, J. L., & Cai, S.-Y. (2011) · Hepatology · doi:10.1002/hep.24047 · Cited by 119
Metadata
- Authors
- Hohenester, S., Oude-Elferink, R. P. J., & Beuers, U.
- Venue
- Seminars in Immunopathology
- Published
- 2009-07-15
- Volume
- 31
- Issue
- 3
- Pages
- 283-307
- ISSN
- 1863-2297 (ISSN-L)
- 1863-2300
- OpenAlex
- W2134613519
- Cited by
- 179
- References
- 71
- FWCI
- 12.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.